Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.
about
Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseasesRecent advances in the management of mucormycosis: from bench to bedsidePharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsLiposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-lys-ala-DAla-lysToxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study.Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin BHypokalaemia-induced rhabdomyolysis after treatment of post-Kala-azar dermal Leishmaniasis (PKDL) with high-dose AmBisome in Bangladesh-a case report.Pharmacokinetics of liposomal amphotericin B in pleural fluid.Liposomal amphotericin B and leishmaniasis: dose and responsePharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosisLiposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infectionsRecent advances in the treatment of mucormycosis.Primary central nervous system phaeohyphomycosis: a review of 101 cases.Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.Antifungal clinical trials and guidelines: what we know and do not knowMultidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis.Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis modelBacterial toxin-triggered drug release from gold nanoparticle-stabilized liposomes for the treatment of bacterial infection.Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.Pharmacotherapy of Candida bloodstream infections: new treatment options, new era.Caspofungin acetate for treatment of invasive fungal infections.Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 studyThe lipid formulations of amphotericin B.Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.Medical management of invasive fungal infections of the central nervous system in pediatric cancer patients.Invasive aspergillosis in patients with hematologic malignancies.New and emerging antifungal agents: impact on respiratory infections.Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infectionsComparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.Combination therapy for mucormycosis: why, what, and how?Liposomal amphotericin B: clinical experience and perspectives.Pharmacokinetics of antifungal agents in children.Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy.Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimensFungal CNS infections in patients with hematologic malignancy.Management of intracranial fungal infections in patients with haematological malignancies.Fungal pneumonia due to molds in patients with hematological malignancies.The emergence of mucormycosis as an important opportunistic fungal infection: five cases presenting to a tertiary referral center for mycology.
P2860
Q24542404-30EC760F-494B-4B09-A35C-4CFF9DDF7233Q24642450-8FC2DEB6-8581-4943-AFCE-13FCFCDA27DDQ27025299-7E756439-ADF1-4B8E-9AF8-51838F787ED3Q28298468-F39CCD55-D49F-4E4D-9E41-98653BDD5B41Q31161843-119C6CD0-559B-49E4-8E02-7F843C49B4BAQ33409652-D2603D1A-1C1A-4C2A-B2CE-FB008C01AECBQ33712955-26365E01-676E-4413-99AB-5BC08AFDFE94Q33722067-ADA3F069-B495-4EBF-897A-868164E56387Q33748160-E0AA728D-4645-448C-8B8C-6B8BBE6D4DD2Q33768861-4C9D5A40-42F7-4C6D-8298-298E41732126Q33929854-0B699E28-76C6-4CE3-9028-7998639B8FDDQ34045435-B304B4AA-FC47-4A84-B275-1BB09717E1CEQ34108585-0B30F448-38AA-4762-917C-E07E946F78EDQ34161213-5553531A-4420-4B04-9537-EFF9406C8683Q34286912-49E156D9-3B55-4303-A952-4A49A57A884DQ34352186-B8486409-1815-4DC0-81C8-583BD5C73134Q34400255-4E21D496-8896-4B02-A143-DBBE00308806Q34510443-1CAFA1B8-DEFD-45D9-B2B0-53E3CA0B23BEQ34680675-C3264184-925E-4743-ABE5-7A60AEAA8F43Q34709457-325AF996-44D0-4786-9810-36AD04336B3EQ34763371-DD85746B-9E83-4298-A90C-B091647D3D8BQ34768471-8FF1DD37-AB43-45A2-A050-335BF9B348FDQ35035091-8F2C0A60-143B-4227-8F53-7CAA50CAB99BQ35150268-A78818CC-5280-4C3F-8DC6-A32FE5D3FB3AQ35183734-964624B7-1F3F-47D1-B7EC-42CABF1E0630Q35385786-D25063EF-4F28-44F0-B435-52CACBF58849Q35513374-0DD72F51-E559-440B-8E5D-904DF495E034Q35616161-7A4AD4A4-6EE7-4C48-A0CA-2DC40E8A47D9Q35627629-3798E25A-6E37-4943-9AF3-F5C769AEBFA3Q35666612-D1FA098B-1F59-4561-B680-11436218758AQ35758926-81794A77-393F-4BF4-89CE-3993A7F46BD5Q35974333-FD661EC4-80B1-4F8F-9CB7-3BD91136DA0FQ36140647-6E2F6991-918A-4385-BAB0-C2145E06360AQ36163345-F8486EAC-BC6A-4DB9-A3A5-BD29585A407DQ36248701-390FC296-354E-49E0-A1AA-F033990EECAAQ36276870-08522315-95C7-43F0-90C4-D98BEE459922Q36278069-96880356-B4CA-4E95-8BE9-82D04A31D3F1Q36286439-6F956EB6-DB60-4C6A-BAB7-E2B772EC9B86Q36616182-88B4DA1C-5E1E-43F7-AEEE-F8D7A7A8A0BFQ36794895-99F24052-8890-47CF-8B77-9F126981D018
P2860
Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Safety, tolerance, and pharmac ...... maximum tolerated dose study.
@ast
Safety, tolerance, and pharmac ...... maximum tolerated dose study.
@en
type
label
Safety, tolerance, and pharmac ...... maximum tolerated dose study.
@ast
Safety, tolerance, and pharmac ...... maximum tolerated dose study.
@en
prefLabel
Safety, tolerance, and pharmac ...... maximum tolerated dose study.
@ast
Safety, tolerance, and pharmac ...... maximum tolerated dose study.
@en
P2093
P2860
P1476
Safety, tolerance, and pharmac ...... maximum tolerated dose study.
@en
P2093
E J Anaissie
I Bekersky
J L Goodman
P2860
P304
P356
10.1128/AAC.45.12.3487-3496.2001
P407
P577
2001-12-01T00:00:00Z